{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:55:42Z","timestamp":1792547742683,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1093\/annonc\/mdy540","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T13:45:38Z","timestamp":1544795138000},"page":"250-258","source":"Crossref","is-referenced-by-count":269,"title":["Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)"],"prefix":"10.1016","volume":"30","author":[{"given":"N.","family":"Boku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Minashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.K.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fumita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-K.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy540_bb0010","unstructured":"Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 v1.0. IARC CancerBase No. 11. International Agency for Research on Cancer; http:\/\/globocan.iarc.fr (16 November 2018, date last accessed)."},{"issue":"10","key":"10.1093\/annonc\/mdy540_bb0015","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy540_bb0020","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","article-title":"Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Smyth","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdy540_bb0025","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdp047","article-title":"Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer","volume":"20","author":"Okines","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy540_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy540_bb0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy540_bb0040","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdy540_bb0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1200\/EDBK_175228","article-title":"Gastric cancer in Asia: unique features and management","volume":"37","author":"Irino","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1093\/annonc\/mdy540_bb0050","first-page":"141","article-title":"Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: a retrospective analysis from a medical center","volume":"37","author":"Kuo","year":"2014","journal-title":"Biomed J"},{"issue":"12","key":"10.1093\/annonc\/mdy540_bb0055","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/S1470-2045(13)70436-4","article-title":"Management of gastric cancer in Asia: resource-stratified guidelines","volume":"14","author":"Shen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1093\/annonc\/mdy540_bb0060","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9742","key":"10.1093\/annonc\/mdy540_bb0065","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"9911","key":"10.1093\/annonc\/mdy540_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1093\/annonc\/mdy540_bb0075","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10111","key":"10.1093\/annonc\/mdy540_bb0080","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdy540_bb0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2018.36.4_suppl.5","volume":"36","author":"Fuchs","year":"2018","journal-title":"J Clin Oncol"},{"issue":"328","key":"10.1093\/annonc\/mdy540_bb0090","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1093\/annonc\/mdy540_bb0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10147-014-0701-7","article-title":"Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance","volume":"20","author":"Geng","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdy540_bb0100","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1093\/annonc\/mdy540_bb0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdy540_bb0110","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdy540_bb0115","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdy540_bb0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1093\/annonc\/mdy540_bb0125","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy540_bb0130","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin Can Res"},{"issue":"1","key":"10.1093\/annonc\/mdy540_bb0135","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"10.1093\/annonc\/mdy540_bb0140","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy540_bb0145","unstructured":"NIH NCI Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE) Version 5, 2017; https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference:5x7.pdf (16 November 2018, date last accessed)."},{"issue":"2","key":"10.1093\/annonc\/mdy540_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdy540_bb0155","author":"Teysuno (S-1)"},{"key":"10.1093\/annonc\/mdy540_bb0160","unstructured":"ELOXATIN (oxaliplatin) Prescribing Information; https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021759s012lbl.pdf (16 November 2018, date last accessed)."},{"key":"10.1093\/annonc\/mdy540_bb0165","unstructured":"XELODA (capecitabine) Prescribing Information; https:\/\/www.gene.com\/download\/pdf\/xeloda_prescribing.pdf (16 November 2018, date last accessed)."},{"issue":"5","key":"10.1093\/annonc\/mdy540_bb0170","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy540_bb0175","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ejca.2011.12.017","article-title":"A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer","volume":"48","author":"Kim","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419310361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419310361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/2\/250\/27970086\/mdy540.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:55:03Z","timestamp":1624697703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419310361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0923753419310361"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy540","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}